CTOs on the Move

Southwest FLA Regional Imaging

www.openmr.com

 
Southwest FLA Regional Imaging is a Punta Gorda, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.openmr.com
  • 329 E Olympia Ave
    Punta Gorda, FL USA 33950
  • Phone: 941.637.9729

Executives

Name Title Contact Details

Similar Companies

3DBio Therapeutics

3DBio is the first company implanting personalized 3D-printed living tissues in patients. #3DBioPrinting​ #3DBio

Lab Co Inc

Lab Co Inc is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ReAlta Life Sciences

ReAlta Life Sciences, Inc. is a biotech company dedicated to harnessing the power of the immune system through its PIC1 technology platform, comprised of a family of over 160 engineered peptides, to address life-threatening medical needs.

BioTheryX

BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through protein modulation, including protein degradation as well as multi-kinase inhibition, to develop treatments that extend and improve the quality-of-life of patients with life-threatening diseases.

Medicenna Therapeutics Corporation

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna`s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna`s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna`s IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.